Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, BioMarin Pharmaceutical Inc reported revenue of $3.22B, up 12.9% year over year. Operating margin was 12.7% and net margin 10.8%, on a free-cash-flow margin of 22.5% with capital expenditure at 3.2% of revenue. Every figure is computed directly from BMRN's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $3.22B | 12.7% | 10.8% |
| FY2024 | $2.85B | 17.0% | 15.0% |
| FY2023 | $2.42B | 7.7% | 6.9% |
| FY2022 | $2.10B | 7.7% | 6.8% |
| FY2021 | $1.85B | -4.5% | -3.5% |
How does BMRN compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.